Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines

Abstract excerpt

BACKGROUND: More than 50% of metastatic melanoma patients have a specific mutation in the serine/threonine kinase BRAF. This results in constitutive activation of the RAS-RAF-MEK-ERK-MAP kinase pathway, which causes uncontrolled cell growth. Vemurafenib (PLX4032) is an oral chemotherapeutic agent that targets the specific mutation V600E in the BRAF protein. Initial response rates are high in patients with BRAF...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Transport and Resistance Mechanisms
• Share to Melanoma and MAPK Pathways
• Share to Pharmacological Effects of Medicinal Plants